The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia

References

• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–1671. doi:10.1038/leu.2016.104
   PubMed Web of Science ®Google Scholar
• Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100(1):116–121. doi:10.1002/cncr.11863
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. doi:10.1038/s41375-020-01111-2
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2U54. doi:10.1200/JCO.2015.64.8899
   PubMed Web of Science ®Google Scholar
• Hjorth-Hansen H, Stenke L, Soderlund S, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015;94(3):243–250. doi:10.1111/ejh.12423
   PubMed Web of Science ®Google Scholar
• Hwang WL, Chen TC, Lin HY, et al. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. Int J Hematol. 2022;115(5):704–712. doi:10.1007/s12185-022-03311-1
   PubMed Web of Science ®Google Scholar
• Visco C, Rodeghiero F, Romano A, et al. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood. 2019;134(20):1708–1711. doi:10.1182/blood.2019001617
   PubMed Web of Science ®Google Scholar
• Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–1825. doi:10.1182/blood-2013-10-534743
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227–2236. doi:10.1056/NEJMoa073255
   PubMed Web of Science ®Google Scholar
• Shoukier M, Borthakur G, Jabbour E, et al. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021;106(11):2853–2858.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385–1415. doi:10.6004/jnccn.2020.0047
   PubMed Web of Science ®Google Scholar
• Ault P, Kantarjian H, Welch MA, et al. Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res 2004;28(6):613–618. doi:10.1016/j.leukres.2003.11.003
   PubMed Web of Science ®Google Scholar
• Aribi A, Kantarjian H, Koller C, et al. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2008;113(6):1338–1343. doi:10.1002/cncr.23718
   PubMed Web of Science ®Google Scholar
• Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012; 9(2): 77-86.
   PubMed Web of Science ®Google Scholar
• [Di] Buduo CA, Currao M, Pecci A, et al. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica. 2016;101(12):1479–1488. doi:10.3324/haematol.2016.146746
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi:10.1056/NEJMoa073275
   PubMed Web of Science ®Google Scholar
• Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10(5):799–806. doi:10.1111/j.1538-7836.2012.04695.x
   PubMed Web of Science ®Google Scholar
• Kim YK, Lee SS, Jeong SH, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res. 2015;50(1):19–25. doi:10.5045/br.2015.50.1.19
   PubMedGoogle Scholar
• Tripathi AK, Shukla A, Mishra S, et al. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. Int J Hematol. 2014;99(4):413–417. doi:10.1007/s12185-014-1533-y
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842–856. doi:10.1177/0091270010375427
   PubMed Web of Science ®Google Scholar
• Wu K, Thapar M, Farrell C, et al. Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in Chinese patients With chronic primary immune thrombocytopenia. Clin Ther. 2015;37(7):1382–1395. doi:10.1016/j.clinthera.2015.03.024
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394. doi:10.1182/blood-2011-12-399667
   PubMed Web of Science ®Google Scholar